Type 2 Diabetes

Type 2 diabetes, formerly called adult-onset or noninsulindependent diabetes, is the most common form of diabetes. People can develop type 2 diabetes at any age, even during childhood. This form of diabetes usually begins with insulin resistance, a condition in which fat, muscle, and liver cells do not use insulin properly. At first, the pancreas keeps up with the added demand by producing more insulin. In time, however, it loses the ability to secrete enough insulin in response to meals. People who are overweight and inactive are more likely to develop type 2 diabetes. Treatment includes taking diabetes medicines, making wise food choices, exercising regularly, controlling blood pressure and cholesterol, and taking aspirin daily—for some.

What is Type 2 Diabetes?

Type 2 diabetes is a common metabolic condition that develops when the body fails to produce enough insulin or when insulin fails to work properly, which is referred to as insulin resistance. Insulin is the hormone that stimulates cells to uptake glucose from the blood to use for energy.

Type 2 Diabetes Diagnosis

Diabetes in Men versus Women

The Risks of Prediabetes

Living With Type 2 Diabetes

What is Insulin Resistance?

Type 2 Diabetes Screening and Prevention

Insulin Resistance Symptoms

Are Low Carbohydrate Diets Good for Type 2 Diabetes?

Fibromyalgia and Diabetes

Insulin Resistance Treatment

Type 2 Diabetes Symptoms

See more featured articles »

Diabetes Mellitus Type 2 Pathophysiology

Vitamin D and Type 2 Diabetes

Is a Plant-Based Diet Good for Type 2 Diabetes?

Type 2 Diabetes Treatment

Does the Keto Diet Increase the Risk of Diabetes?

Insulin Resistance and Parkinson's Disease

What is Diabetes?

Insulin Resistance Pathophysiology

Insulin Medication

Insulin Resistance Diagnosis

Causes of Insulin Resistance

Latest Type 2 Diabetes News and Research

Tirzepatide cuts fat mass by 35% while preserving skeletal muscle

Tirzepatide cuts body fat while preserving skeletal muscle in real-world study

2 Oct 2026

Could the gut be priming the body for a more severe stroke?

Gut bacteria may prime immune cells to worsen stroke damage

2 Oct 2026

Postpartum GLP-1 prescriptions rise sharply among U.S. women

More U.S. women are being prescribed GLP-1 medications after giving birth, particularly those diagnosed with diabetes, according to new research from the USC Schaeffer Center for Health Policy & Economics.

1 Oct 2026

CBL-514 injection reduces visceral and subcutaneous fat in trials

Details of a new injection that targets fat cells will be released at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2).

1 Oct 2026

Gut bacterial metabolite worsens brain damage after stroke, study finds

Researchers at LMU have discovered how a metabolite produced by gut bacteria can influence brain damage after stroke.

1 Oct 2026

Mauritius becomes first country to reverse type 2 diabetes epidemic

New research to be presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and published in The Lancet Diabetes & Endocrinology shows that the small island nation of Mauritius is the first country in the world to prove it is reversing the type 2 diabetes epidemic using the objective gold standard testing method of the 2-hour oral glucose tolerance test (2 hour OGTT).

1 Oct 2026

Real-world data reveals higher reported GLP-1 side effects in female patients

The second of a Series of papers presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and published in The Lancet Obstetrics, Gynaecology & Women's Health discusses the wide-ranging issues relating to use of GLP-1 RA drug use in women.

1 Oct 2026

GLP-1 receptor agonist exposure shows no link to major adverse pregnancy outcomes

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and published in The Lancet Obstetrics, Gynaecology & Women's Health shows that, following a review and meta-analysis of available studies, use of glucagon-like peptide-1 receptor agonists (GLP-1 RA) drugs for diabetes and weight management in women living with diabetes is not associated with adverse pregnancy outcomes in most cases.

1 Oct 2026

Early-onset type 2 diabetes trial demonstrates significant 24-week fat loss

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and published in The Lancet Regional Health Americas journal shows that in people who have developed early onset type 2 diabetes (EOT2D) (aged under 45 years), around half these T2D cases can be reversed with a low-energy diet combined with a structured exercise program.

1 Oct 2026

Study examines the real-world use of GLP-1 RA drugs in children and young people

New research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) has examined the real-world use of GLP-1 receptor agonist (GLP-1 RA) drugs in children and young people in Germany, Austria and Luxembourg.

30 Sep 2026

Novo Nordisk Foundation funds genomic research into metabolic diseases

The Novo Nordisk Foundation has committed $53 million to renew and expand the Novo Nordisk Foundation Center for Genomic Mechanisms of Disease at the Broad Institute, led by managing director Kasper Lage.

30 Sep 2026

Researchers found a curious mitochondrial pattern in people who moved more

Researchers found that greater self-reported activity, walking, and accelerometer-measured light activity were associated with higher mitochondrial DNA copy number in 256 healthy middle-aged adults. The cross-sectional findings cannot establish causation, and the very low amount of vigorous activity means they do not show that light movement is more beneficial than higher-intensity exercise.

29 Sep 2026

$5.7 million NIH grant supports research on why lean people develop insulin resistance

A Wayne State University research team was awarded a $5.7 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health focused on discovering the biological mechanisms that may help explain why some lean people develop insulin resistance while some people with obesity remain sensitive to insulin.

29 Sep 2026

First EU Screening Week urges citizens to know their numbers

At a dedicated press conference at the EASD Annual Meeting in Milan, organized by the European Diabetes Forum (EUDF), three leading European cardiometabolic scientific associations - the European Society of Cardiology (ESC), the European Association for the Study of Diabetes (EASD) and the European Association for the Study of Obesity (EASO) - joined European Commissioner for Health and Animal Welfare Olivér Várhelyi to welcome the launch of the first-ever EU Screening Week.

29 Sep 2026

Greater variation in blood pressure associated with higher risk of death and strokes

Greater variation in blood pressure between research visits was associated with a higher risk of death in a study of more than 57,000 UK Biobank participants.

29 Sep 2026

Canadian study links neighborhood poverty levels to type 2 diabetes risk

The area in which someone lives strongly influences their risk of developing type 2 diabetes, new research from Canada being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) suggests.

29 Sep 2026

Short voice recordings could screen patients for type 2 diabetes

Signs of type 2 diabetes can be detected in just a few seconds from the way someone talks, new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) shows.

29 Sep 2026

New registry data shows semaglutide does not cause pancreatic cancer

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) shows no link between semaglutide use and pancreatic cancer using nationwide registry data from Denmark, Sweden and Norway.

29 Sep 2026

Exercise may reshape your gut microbiome to support recovery

Research reveals how exercise alters gut microbes, influencing recovery and proposing 'intestinal rehabilitation' for those with limited exercise capacity.

29 Sep 2026

From espresso to filter coffee, brewing may shape what reaches your gut

A focused narrative review traces how caffeine, chlorogenic acids, and coffee fibers move through the gut and interact with microbes. The authors identify plausible links between the microbiome and liver health, but human studies have not shown that microbiome changes cause coffee’s reported metabolic benefits.

28 Sep 2026